P63 and P73: Teammates or adversaries?  by Ratovitski, Edward et al.
	 p r e v i e w sP63 and P73: Teammates or adversaries?
The status and interrelationship of p53 family members are critical elements in tumor progression. An intriguing paper in 
this issue of Cancer Cell (Rocco et al., 2006) reveals a new twist in the interactions between p63 and p73 following DNA dam-
age, underscoring a role for p73 in the proapoptotic regulation of Puma, Noxa, and Bcl-2 in head and neck squamous cell 
carcinomas (HNSCC). These data define a pathway in which DNp63α promotes survival in squamous epithelial malignancy 
by repressing a p73-dependent proapoptotic transcriptional program, suggesting that p63 levels and p73 status may be key 
determinants of tumor response in patients with HNSCC.At the cellular level, tumor progression 
usually involves blockage of normally 
regulated cell cycle control and apopto-
sis mediated by tumor suppressor genes. 
Inactivation of tumor suppressor genes or 
activation of protooncogenes can lead to 
a lack of proper control, especially under 
stress, leading to clonal outgrowth and 
tumor progression. These oncogenic 
events are evolving as important deter-
minants in the response of human tumors 
to commonly used DNA damaging treat-
ments. Head and neck squamous cell 
carcinomas (HNSCC) are malignancies 
derived from cells within the basal epi-
thelia of the aerodigestive mucosa and 
are usually treated with platinum-based 
chemotherapy and radiation (Forastiere et 
al., 2001). P53 mutations are common in 
HNSCC, and the role of other p53 family 
members in this disease continues to be 
elucidated.
Several years ago, p73 and p63 joined 
the ranks of the p53 family. Both of these 
new members give rise to various protein 
isotypes predicting complex transcriptional 
activity. In addition to p63 and p73 isotypes 
capable of transactivating downstream tar-
get gene expression (TA isotypes), both 
genes also expressed dominant nega-
tive inhibitory isoforms (∆N-isotypes). 
Amplification and overexpression of 
∆Np63α was found to be the most com-
mon oncogenic event in primary HNSCC 
(Hibi et al., 2000). Specific amplification 
of p63 was just confirmed in over half of 
all squamous cell carcinomas of the lung, 
supporting its role in all common squa-
mous cell carcinomas (Tonon et al., 2005). 
Moreover, ∆Np63 isoforms induced prolif-
eration and growth of tumor cells in vitro 
and in vivo, and led to β-catenin-increased 
accumulation and signaling (Patturajan et 
al., 2002). We recently established that 
p63 is capable of regulating distinct sets of 
downstream target genes through a unique 
p63 cis element (Osada et al., 2005). One 
crucial target of ∆Np63α was found to be 
HSP-70, a stress response protein known 
to be a key determinant of cell death and 
cell transformation (Wu et al., 2003). Thus, 
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tribute to tumorigenesis through direct 
regulation of target genes, inhibition of the 
transactivation activity of p53 family mem-
bers, or direct protein-protein interactions 
in key proliferative pathways.
What happens if ∆Np63α is removed 
from malignant cells overexpressing this 
oncogenic protein? After RNAi knock-
down, no significant effect on cell viability 
was observed at early time points, but 
after 48 hr, a large fraction of cells under-
went obvious death accompanied by 
cleavage of the poly(ADP)-ribosylating 
enzyme PARP-1. Furthermore, Rocco et 
al. show in the current study that inhibition 
of endogenous ∆Np63α by lentivirus RNAi 
in HNSCC cells induces the proapoptotic 
bcl-2 family members Puma and Noxa, 
suggesting that ∆Np63α is required for 
cell survival (Rocco et al., 2006). Induction 
of these genes following knockdown of 
∆Np63α by RNAi is independent of p53, 
and instead requires transactivation of 
p73 isoforms. These data suggest that in 
most HNSCC tumors, TAp73 is function-
ally inactivated by high levels of ∆Np63α. 
In contrast, the rare HNSCC tumors with 
low ∆Np63α levels apparently bypass the 
requirement for p63-mediated p73 inhibi-
tion through upregulation of bcl-2 expres-
sion. They also found that bcl-2 expression 
rescues cells from death following loss of 
∆Np63α and is inversely correlated with 
∆Np63α levels in HNSCC cells.
∆Np63α could conceivably inhibit the 
activity of p73 by a variety of mechanisms, 
including a direct association of both pro-
teins or competitive interaction of p63 and 
p73 with similar cis elements in down-
stream gene target promoters (Rocco et 
al., 2006). Posttranslational modifications 
of p73 following DNA damage might also 
contribute to p73 activation and its promot-
er selectivity (Strano et al., 2005). This fact 
might explain differences in proapoptotic 
genes induced by p73 upon DNA dam-
age versus those they find induced fol-
lowing inhibiton of p63 with RNAi (Strano 
et al., 2005). Consistent with this report, 
a prior study found that overexpression r inc. of p73 in the absence of DNA damage 
leads to induction of endogenous Puma 
mRNA and protein (Melino et al., 2004). 
The new findings support the notion that 
endogenous ∆Np63α suppresses the pro-
apoptotic activity of p73 both through its 
direct association with p73 and through 
direct repression of p73-dependent tran-
scription.
From the work presented here, it is 
becoming clear that in addition to the 
known role of p53, both p63 (∆Np63α) 
and p73 are critical mediators of cell 
death following chemotherapy in HNSCC. 
∆Np63α was shown to be dramatically 
downregulated following DNA damage, 
and p63 levels correlated with patient 
response to cisplatin-based treatment 
(Zangen et al., 2005). This report sug-
gests that p73-mediated cell death fol-
lowing DNA damage may represent the 
cumulative effect of increased p73 levels 
in addition to decreased p63-mediated 
transcriptional inhibition. This new discov-
ery may also shed light on the connec-
tion between accumulation of p73 and the 
loss of ∆Np63α levels necessary for the 
apoptotic program activation in HNSCC. 
The data further explain the lack of p73 or 
PUMA mutations in HNSCC, since p73 is 
inactivated by ∆Np63α overexpression in 
most of these tumors.
Head and neck cancers are commonly 
treated with a combination of DNA dam-
aging agents, including radiation and/or 
chemotherapy. Although p53 status and 
response to chemotherapy may be linked, 
many studies published over the years 
have failed to show a direct connection 
between p53 mutational status and favor-
able patient response to chemotherapy. 
The new work presented here may in part 
explain previously observed prognos-
tic correlations involving p63 and bcl-2 
(Massion et al., 2003; Zangen et al., 2005; 
Andrews et al., 2004). For head and neck 
cancers expressing ∆Np63α, downregula-
tion of ∆Np63α and subsequent activation 
of p73 may be an important mechanism for 
a favorable response of patients to treat-
ment (Massion et al., 2003; Zangen et al., 
	 p r e v i e w s2005). Thus, tumors that have circum-
vented the requirement of p63-mediated 
survival may exhibit resistance to common 
cancer treatments (Rocco et al., 2006).
In contrast, upregulation of bcl-2 
through alternative mechanisms may 
identify tumors that are resistant to the 
proapoptotic effect of these treatment 
modalities regardless of p53 family mem-
ber status. Specific bcl-2 inhibitors show 
promise as cancer therapeutics in lung and 
other cancers. Other agents hold promise 
for increasing wild-type p53 levels, thus 
abrogating the p63 survival function. It 
would be interesting to explore whether 
novel biologic treatments that abrogate 
EGFR signaling in combination with DNA 
damaging agents can also overcome 
this resistance. A recent study showed 
that the addition of an EGFR antibody to 
local radiation therapy and platinum treat-
ment markedly improved patient survival. 
Understanding the status of all p53 family 
members in HNSCC is crucial for devel-
oping more individualized combinations 
with standard DNA damaging agents and 
newer molecular therapies.2 
In 2001, a seminal paper by Sicinski and 
coworkers (Yu et al., 2001) reported that 
mice lacking Cyclin D1 were refractory to 
tumorigenesis induced by MMTV-driven 
Ha-ras and c-neu/erbB-2 oncogenes. c-
neu/erbB-2 is the rodent ortholog of the 
human HER-2 receptor gene frequently 
overexpressed in human breast carci-
nomas. Indeed, HER-2 is one of the few 
oncogenes already targeted in the clinic 
by means of specific monoclonal antibod-
ies (reviewed in Hynes and Lane, 2005).
Earlier studies by Sicinski et al. (1995), 
then in the Weinberg laboratory, and by 
Fantl et al. (1995) in the Dickson labora-
tory had described that ablation of cyclin 
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(Yu et al., 2001). Intriguingly, c-neu/erbB-
2 and Ha-ras oncogenes induced other 
types of tumors (mainly salivary gland 
tumors) and efficiently transformed cyclin 
D1 null fibroblasts in culture (Yu et al., 
2001), indicating that the selective role of 
Cyclin D1 in mediating c-neu/erbB-2 and 
Ha-ras oncogenesis is unique to mam-
mary epithelial cells (Figure 1).
Cyclin D1 is not an obvious drugga-
ble target. Yet, one of the main biological 
activities of Cyclin D1 involves activation 
of its partners Cdk4 and Cdk6, two kinas-
es whose catalytic activity is absolutely 
dependent upon binding of any of the 
D-type Cyclins (reviewed in Malumbres 
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